FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154017844> ?p ?o ?g. }

• W2154017844 endingPage "333" @default.
• W2154017844 startingPage "327" @default.
• W2154017844 abstract "We examined the inhibitory mechanisms of fluvastatin on FBS-induced vascular hypertrophy assessed by organ-cultured rat tail artery.After 5 days of culture with 10% FBS, hyperplastic morphological changes in the media layer were induced. Treatment with 1 mumol/L fluvastatin significantly inhibited these changes. In the FBS-cultured arteries, the protein expression ratio of alpha-actin/beta-actin was significantly decreased, indicating the change to synthetic phenotype. Fluvastatin restored the decreased expression ratio, and the addition of mevalonate (100 mumol/L) suppressed this recovery. In accordance with the synthetic morphological changes, the absolute force of contractions induced by stimuli was decreased. Fluvastatin treatment also restored the decreased contractility, and the addition of mevalonate suppressed this recovery. In the arteries cultured with FBS, extracellular signal-regulated kinase 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (p38MAPK) phosphorylation were significantly increased. Fluvastatin inhibited these phosphorylations, and mevalonate prevented the action of fluvastatin.These results suggest that fluvastatin inhibits vascular smooth muscle phenotype modulation to synthetic phenotype and proliferation by inhibiting the local metabolic pathway of cholesterol in smooth muscle cells, which inhibits hyperplastic changes in the vascular wall. The antihyperplastic actions by statins may be induced by inhibiting the ERK1/2 and p38MAPK activities, possibly through inhibition of prenylated Ras. We examined the inhibitory mechanisms of fluvastatin on FBS-induced vascular hypertrophy assessed by organ-cultured artery. Results suggest that fluvastatin inhibits vascular smooth muscle phenotype modulation and proliferation by inhibiting the ERK1/2 and p38MAPK activities through depletion of mevalonate in smooth muscle cells, resulting in inhibiting vascular hyperplastic changes." @default.
• W2154017844 created "2016-06-24" @default.
• W2154017844 creator A5006676797 @default.
• W2154017844 creator A5023789798 @default.
• W2154017844 creator A5038416437 @default.
• W2154017844 creator A5050233578 @default.
• W2154017844 creator A5071552581 @default.
• W2154017844 date "2005-02-01" @default.
• W2154017844 modified "2023-10-18" @default.
• W2154017844 title "Fluvastatin Prevents Vascular Hyperplasia by Inhibiting Phenotype Modulation and Proliferation Through Extracellular Signal-Regulated Kinase 1 and 2 and p38 Mitogen-Activated Protein Kinase Inactivation in Organ-Cultured Artery" @default.
• W2154017844 cites W1912592877 @default.
• W2154017844 cites W1924405787 @default.
• W2154017844 cites W1945199177 @default.
• W2154017844 cites W1965418020 @default.
• W2154017844 cites W1966767094 @default.
• W2154017844 cites W1975915718 @default.
• W2154017844 cites W1981930770 @default.
• W2154017844 cites W1988994440 @default.
• W2154017844 cites W2005294216 @default.
• W2154017844 cites W2012821845 @default.
• W2154017844 cites W2015998585 @default.
• W2154017844 cites W2033831171 @default.
• W2154017844 cites W2037085464 @default.
• W2154017844 cites W2051441972 @default.
• W2154017844 cites W2067236087 @default.
• W2154017844 cites W2071124826 @default.
• W2154017844 cites W2072238317 @default.
• W2154017844 cites W2074292738 @default.
• W2154017844 cites W2096334465 @default.
• W2154017844 cites W2123886313 @default.
• W2154017844 cites W2133227794 @default.
• W2154017844 cites W2134335220 @default.
• W2154017844 cites W2137570167 @default.
• W2154017844 cites W2145831571 @default.
• W2154017844 cites W2148463229 @default.
• W2154017844 cites W2150499586 @default.
• W2154017844 cites W2155598961 @default.
• W2154017844 cites W2160761045 @default.
• W2154017844 cites W2162694078 @default.
• W2154017844 cites W2171324002 @default.
• W2154017844 cites W2322095705 @default.
• W2154017844 cites W2324841714 @default.
• W2154017844 cites W2329543325 @default.
• W2154017844 doi "https://doi.org/10.1161/01.atv.0000152611.50953.e2" @default.
• W2154017844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15591221" @default.
• W2154017844 hasPublicationYear "2005" @default.
• W2154017844 type Work @default.
• W2154017844 sameAs 2154017844 @default.
• W2154017844 citedByCount "29" @default.
• W2154017844 countsByYear W21540178442013 @default.
• W2154017844 countsByYear W21540178442014 @default.
• W2154017844 countsByYear W21540178442017 @default.
• W2154017844 countsByYear W21540178442020 @default.
• W2154017844 countsByYear W21540178442022 @default.
• W2154017844 crossrefType "journal-article" @default.
• W2154017844 hasAuthorship W2154017844A5006676797 @default.
• W2154017844 hasAuthorship W2154017844A5023789798 @default.
• W2154017844 hasAuthorship W2154017844A5038416437 @default.
• W2154017844 hasAuthorship W2154017844A5050233578 @default.
• W2154017844 hasAuthorship W2154017844A5071552581 @default.
• W2154017844 hasBestOaLocation W21540178441 @default.
• W2154017844 hasConcept C126322002 @default.
• W2154017844 hasConcept C132149769 @default.
• W2154017844 hasConcept C134018914 @default.
• W2154017844 hasConcept C184235292 @default.
• W2154017844 hasConcept C2776329913 @default.
• W2154017844 hasConcept C2778417548 @default.
• W2154017844 hasConcept C2779395532 @default.
• W2154017844 hasConcept C2992686903 @default.
• W2154017844 hasConcept C51551487 @default.
• W2154017844 hasConcept C71924100 @default.
• W2154017844 hasConcept C86803240 @default.
• W2154017844 hasConcept C95444343 @default.
• W2154017844 hasConcept C97029542 @default.
• W2154017844 hasConceptScore W2154017844C126322002 @default.
• W2154017844 hasConceptScore W2154017844C132149769 @default.
• W2154017844 hasConceptScore W2154017844C134018914 @default.
• W2154017844 hasConceptScore W2154017844C184235292 @default.
• W2154017844 hasConceptScore W2154017844C2776329913 @default.
• W2154017844 hasConceptScore W2154017844C2778417548 @default.
• W2154017844 hasConceptScore W2154017844C2779395532 @default.
• W2154017844 hasConceptScore W2154017844C2992686903 @default.
• W2154017844 hasConceptScore W2154017844C51551487 @default.
• W2154017844 hasConceptScore W2154017844C71924100 @default.
• W2154017844 hasConceptScore W2154017844C86803240 @default.
• W2154017844 hasConceptScore W2154017844C95444343 @default.
• W2154017844 hasConceptScore W2154017844C97029542 @default.
• W2154017844 hasIssue "2" @default.
• W2154017844 hasLocation W21540178441 @default.
• W2154017844 hasLocation W21540178442 @default.
• W2154017844 hasOpenAccess W2154017844 @default.
• W2154017844 hasPrimaryLocation W21540178441 @default.
• W2154017844 hasRelatedWork W1973796947 @default.
• W2154017844 hasRelatedWork W1988519514 @default.
• W2154017844 hasRelatedWork W1988664512 @default.
• W2154017844 hasRelatedWork W2013052548 @default.
• W2154017844 hasRelatedWork W2058202339 @default.
• W2154017844 hasRelatedWork W2070643674 @default.

• next